Fig. 3. Prophylactic and therapeutic effects of human H7N9 mAbs in mice i.n. challenged with 10 LD₅₀ of A/Anhui/1/2013 H7N9.

(A) Mice were i.p. injected with 100 μg (equivalent of 5 mg/kg) or 20 μg (equivalent of 1 mg/kg) of the indicated mAbs (as human IgG1 unless otherwise specified) one day before viral challenge; % survival (less than 20% weight loss) and % body weight of survived mice were plotted over time. (B) Mice were i.p. injected with 100 μg of the indicated mAbs one day after viral challenge; % survival and % body weight of survived mice were plotted over time. Arrows indicate the time when mAbs were administered. Control groups of a non-H7 placebo mAb and PBS were included. Data for each group were combined from 1–2 experiments and shown as mean – SEM. Asterisk symbols denote statistical significance with P values < 0.05.